ArticleNature2018
Structure of the µ-opioid receptor-G
Open access · greenAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 410 papers.
0numbers the graph read from it
0cells of the map it votes in
410citing papers in PubMed
30.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
410 citing papers in PubMed, 675 citations in OpenAlex.
- Innovative Approach Reveals How Receptors Control G Protein State Equilibria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Atomic, structural and molecular insights into GPCR ligand binding and signalling.Nature reviews. Molecular cell biology · 2026Review
- Smoking Abstinence Elicits Hyperalgesia: Neural Mechanism, Clinical Implications, and Pharmacological Managements.CNS neuroscience & therapeutics · 2026Review
- Structure-guided allosteric modulation of the delta opioid receptor.Nature communications · 2026Article
- G Protein-Mediated Allosteric Modulation of Ligand Binding in Class A GPCRs: Receptor-Ligand-Transducer Ensembles in Disease and Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficient experimental characterization of the GPCRome via deep receptor scanning.Nature communications · 2026Article
- Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.Acta pharmaceutica Sinica. B · 2026Review
- GαNature communications · 2026Article
- Elucidating the Structure and Activation Mechanisms of GPCRs Using Modern Computational and AI Tools.Cell biochemistry and biophysics · 2026Review
- Genome editing-based refinement of GPCR visualization in mice using the oxytocin receptor as a model.Scientific reports · 2026Article
- Structural and dynamic studies uncover a distinct allosteric modulatory site at the µ-opioid receptor.Nature communications · 2026Article
- G protein regulatory network shapes magnitude and kinetics of behavioral responses in an engineered opioid receptor model.The Journal of biological chemistry · 2026Article
- Structured water molecules drive activation and G protein selectivity in the GPR174 receptor.PLoS biology · 2026Article
- Activation dynamics of a water-soluble human mu-opioid receptor.The Journal of biological chemistry · 2026Article
- Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets.Cell · 2026Article
- Identification of Subtype-Selective Binding Sites in the Opioid Receptor Family.Journal of chemical information and modeling · 2026Article
- Mitragynine and Morphine Stabilize Different Conformations of the μ‑Opioid Receptor as Revealed by Molecular Dynamics Simulation Studies.ACS omega · 2026Article
- A complex interplay of various intracellular motifs determines G protein binding and activation of muscarinic receptors.Scientific reports · 2026Article
- Structural insights into coffee bitter taste perception by TAS2R43 receptor.Nature structural & molecular biology · 2026Article
- Mechanistic insights into ligand selectivity inActa pharmaceutica Sinica. B · 2026Article
350 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 3 countries.
Antoine Koehl *Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Hongli Hu *Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Shoji Maeda *Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Yan ZhangDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Qianhui QuDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Joseph M PaggiDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Naomi R LatorracaDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Daniel HilgerDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Roger DawsonRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F.Hoffmann-La Roche, Basel, Switzerland.
Hugues MatileRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F.Hoffmann-La Roche, Basel, Switzerland.
Gebhard F X SchertlerLaboratory of Biomolecular Research, Paul Scherrer Institute, Villigen, Switzerland.
Sebastien GranierInstitut de Génomique Fonctionnelle, INSERM, Montpellier, France.
William I WeisDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Ron O DrorDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. Aashish.Manglik@ucsf.edu.
Georgios SkiniotisDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA. yiorgo@stanford.edu.
Brian K KobilkaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. kobilka@stanford.edu.
Stanford University · USRoche (Switzerland) · CHInserm · FRPaul Scherrer Institute · CHUniversity of California, San Francisco · US
Funding
Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9MStructure and dynamics of G protein coupled receptor-G protein complexesR01GM083118 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOBILKA, BRIAN K, SKINIOTIS, GEORGIOS · 2008 to 2023
$8.3MMolecular Biophysics Training Program at StanfordT32GM008294 · NIGMS · STANFORD UNIVERSITY · PI HUANG, KERWYN C. · 1989 to 2019
$7.4MStructural Basis of Opioid Receptor FunctionR37DA036246 · NIDA · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 2013 to 2020
$4.2MNIDA NIH HHS R37 DA036246NIGMS NIH HHS R01 GM083118NIGMS NIH HHS T32 GM008294
Abstract
The μ-opioid receptor (μOR) is a G-protein-coupled receptor (GPCR) and the target of most clinically and recreationally used opioids. The induced positive effects of analgesia and euphoria are mediated by μOR signalling through the adenylyl cyclase-inhibiting heterotrimeric G protein G
Indexed as
Cryoelectron MicroscopyAnimalsBinding SitesEnkephalin, Ala(2)-MePhe(4)-Gly(5)-FemaleGTP-Binding Protein alpha Subunits, Gi-GoGTP-Binding Protein alpha Subunits, GsHumansLigandsMiceMice, Inbred BALB CMolecular Dynamics SimulationMorphinansProtein StabilityReceptors, Adrenergic, beta-2Receptors, Opioid, muEnkephalin, Ala(2)-MePhe(4)-Gly(5)-GTP-Binding Protein alpha Subunits, Gi-GoGTP-Binding Protein alpha Subunits, GsLigandsMorphinansReceptors, Adrenergic, beta-2Receptors, Opioid, mu
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.